Beam Therapeutics Inc
NASDAQ:BEAM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.22
45.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beam Therapeutics Inc
Beam Therapeutics Inc
Other
Beam Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
Other
-$631k
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
-$100m
|
CAGR 3-Years
45%
|
CAGR 5-Years
22%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$5.7B
|
CAGR 3-Years
-238%
|
CAGR 5-Years
-114%
|
CAGR 10-Years
-4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$127m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$398.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$1.3B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Beam Therapeutics Inc
Glance View
Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.
See Also
What is Beam Therapeutics Inc's Other?
Other
-631k
USD
Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Other amounts to -631k USD.
What is Beam Therapeutics Inc's Other growth rate?
Other CAGR 3Y
33%
Over the last year, the Other growth was -232%. The average annual Other growth rates for Beam Therapeutics Inc have been 33% over the past three years .
You don't have any saved screeners yet
